Business Context and Reporting Period
Company: Vivos Therapeutics, Inc. (VVOS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Vivos is a medical technology company treating obstructive sleep apnea (OSA) via proprietary oral appliances ("The Vivos Method"). The company is executing a strategic pivot from a legacy dentist-focused model to a medical-provider focused model involving acquisitions and alliances with sleep centers. A key milestone was the June 2025 acquisition of The Sleep Center of Nevada (SCN).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $5.14 million | $3.02 million |
| Gross Profit | $3.06 million | $1.51 million |
| Gross Margin | 60% | 50% |
| Operating Loss | $(6.62) million | $(3.92) million |
| Net Loss | $(7.75) million | $(3.86) million |
| Net Loss Per Share (Basic/Diluted) | $(0.52) | $(0.45) |
| Cash and Cash Equivalents | $2.11 million | $2.34 million |
| Total Debt (Current + Long-term) | $7.72 million | $8.82 million |
| Stockholders' Equity | $(1.14) million | $(1.49) million |
Cash Flow: Net cash used in operating activities was $6.01 million. Net cash provided by financing activities was $6.11 million, driven by warrant exercises and debt issuance.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 70% ($2.13 million) year-over-year. This was driven by a $2.50 million increase in service revenue, primarily from sleep testing services ($2.30 million) and treatment center revenue ($0.89 million) resulting from the SCN acquisition.
- Product Revenue Decline: Product revenue decreased 21% to $1.44 million due to a strategic shift away from VIP dentist enrollments and increased discounts on appliance sales.
- Expense Surge: General and Administrative (G&A) expenses more than doubled to $8.97 million, largely due to $1.5 million in costs associated with operating SCN and increased professional fees. Depreciation and amortization also rose significantly due to new assets from the acquisition.
- Equity Position: Stockholders' equity improved from a deficit of $1.49 million to $1.14 million following equity financing activities, though the company remains in a deficit position.
Outlook, Risks, and Contingencies
- Liquidity and Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. Cash on hand ($2.11 million) is insufficient to fund operations for the next 12 months without additional financing. The company is actively seeking equity financing and evaluating debt restructuring.
- Nasdaq Compliance: The company received a notice from Nasdaq on April 17, 2026, stating it failed to meet the minimum stockholders' equity requirement of $2.5 million. The company has 45 days to submit a compliance plan and may face delisting if compliance is not achieved by October 14, 2026.
- Strategic Pivot Risks: The new medical-provider model is unproven. Success depends on integrating SCN, managing staffing, securing insurance reimbursements, and generating sufficient patient volume to cover the substantial debt incurred for the acquisition.
- Legal Settlement: In March 2026, the company settled litigation with Ortho-Tain, Inc. The settlement involves a confidential payment and restrictions on using the term "Guide" in product names and soliciting dentists for specific tooth positioner products.
- Clinical Trial Status: A clinical study with Stanford University regarding the DNA appliance was placed on hold in late 2024 due to low recruitment and remains on hold as of Q1 2026.
Investor Verification Checklist
- Capital Raise Status: Verify if the company has secured the additional equity financing required to meet the Nasdaq $2.5 million equity requirement and fund operations through 2027.
- SCN Integration: Monitor patient volume and revenue growth from the Sleep Center of Nevada (SCN) to determine if the acquisition is generating the projected cash flows to service the $8.3 million acquisition debt.
- Nasdaq Hearing Outcome: Track the acceptance of the company's compliance plan by the Nasdaq Listing Qualifications Staff and any subsequent extension periods granted.
- Debt Service Obligations: Review the terms of the Streeterville Capital note (9% interest, monthly redemption rights) and the Avondale Capital note to assess immediate cash outflow requirements.
- Product Mix Shift: Confirm the trajectory of the shift from low-margin product sales to higher-margin service revenue and whether the decline in VIP enrollment revenue is stabilizing.